US 12070500
Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 12070500 (Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis) held by VACCINEX, INC. expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- VACCINEX, INC.
- Grant date
- Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545